Indications |
Oral Biliary tract infections Adult: 250-500 mg every 6 hr. Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
Oral Endocarditis Adult: 250-500 mg every 6 hr. Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
Oral Otitis media Adult: 250-500 mg every 6 hr. Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
Oral Peritonitis Adult: 250-500 mg every 6 hr. Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
Oral Bronchitis Adult: 250-500 mg every 6 hr. Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
Oral Perinatal streptococcal infections Adult: 250-500 mg every 6 hr. Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
Oral Gastroenteritis Adult: 250-500 mg every 6 hr. Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
Oral Listeriosis Adult: 250-500 mg every 6 hr. Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
Oral Susceptible infections Adult: 250-500 mg every 6 hr. Child: 50-100 mg/kg daily, given in equally divided doses every 6 hr. Max: 2-4 g/day. Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
Oral Typhoid and paratyphoid fever Adult: 1-2 g every 6 hr for 2 wk in acute infections and 4-12 wk in carriers. Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session. Oral Uncomplicated gonorrhoea Adult: 2 g with 1 g of probenecid as a single dose, recommended to be repeated in female patients. Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
Intravenous Intrapartum prophylaxis against group B Streptoccocal infection in neonates Adult: Initially, 2 g via inj followed by 1 g every 4 hr until delivery. Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
Injection As supplement in systemic therapy for treatment of susceptible infections Adult: For intrapleural or intraperitoneal injections: 500 mg daily, dissolved in 5-10 ml of water. For intra-articular inj: 500 mg daily, dissolved in up to 5 ml of water or a solution of 0.5% procaine HCl. Child: ½ the adult dose. Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
Parenteral Meningitis Adult: 150-200 mg/kg daily in equally divided doses every 3-4 hr. May initiate with IV admin followed by IM injections. Child: and infants: 150 mg/kg daily in divided doses. Neonates: <1 wk: 50 mg/kg every 12 hr; older neonates: 50 mg/kg every 8 hr. Max: 3 g/day. May initiate with IV admin followed by IM injections. Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
Intravenous Septicaemia Adult: 150-200 mg/kg daily. Initiate with IV admin for at least 3 days, then continue with IM inj every 3-4 hr. Continue treatment for at least 48-72 hr after the patient has become asymptomatic or when there is evidence of bacterial eradication. Recommended treatment duration for infections caused by group-A β-haemolytic streptococci: At least 10-days to prevent occurrence of acute rheumatic fever or acute glomerulonephritis. Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
Parenteral Susceptible infections Adult: 250-500 mg every 6 hr, can be given via IM or slow IV inj over 3-5 minutes or infusion. Child: 100-400 mg/kg daily in divided doses every 6 hr. Max: 12 g daily. Dose can be given via IM or slow IV inj over 3-5 minutes or infusion. Renal impairment: Patients undergoing haemodialysis should receive an additional dose after the session.
Reconstitution: Reconstitute according to manufacturer's instructions. See lit. Incompatibility: Y-site incompatibility: Amphotericin B cholesteryl sulfate complex, ondansetron, sargramostim, verapamil, vinorelbine epinephrine, fluconazole, hydralazine, midazolam. Syringe incompatibility: Erythromycin lactobionate, gentamicin, lincomycin, metoclopramide, hydromorphone, kanamycin. Admixture incompatibility: Amikacin, hydralazine, prochlorperazine, chlorpromazine, dopamine, gentamicin. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contraindications |
Hypersensitivity; infectious mononucleosis. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warnings / Precautions |
Renal failure; patients with lymphatic leukaemia or HIV infections; pregnancy and lactation. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse Reactions |
GI upset, nausea, vomiting, diarrhoea; blood dyscrasias; urticaria, exfoliative dermatitis, rash; fever, seizures; interstitial nephritis. Potentially Fatal: Anaphylactic shock; pseudomembranous colitis; neuromuscular hypersensitivity; electrolyte imbalance. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Overdose Reactions |
Discontinue medication, treat symptomatically, and institute supportive measures as required. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Drug Interactions |
Simultaneous use with oral contraceptives may lead to increased risk of breakthrough bleeding and reduced efficacy of the contraceptive. Skin rash increased with allopurinol. Probenecid increases blood levels. Synergism with β-lactamase inhibitors, clavulanic acid or sulbactam, penicillinase-stable drugs eg, cloxacillin or flucloxacillin and aminoglycosides. Potentially Fatal: Increases disulfiram and anticoagulant effects. See Below for More ampicillin Drug Interactions |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Food Interactions |
Reduced absorption with food. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mechanism of Actions |
Ampicillin exerts bactericidal action on both gm+ve and gm-ve organisms. Its spectrum includes gm+ve organisms eg, S pneumoniae and other Streptococci, L monocytogenes and gm-ve bacteria eg, M catarrhalis, N gonorrhoea, N meningitidis, E coli, P mirabilis, Salmonella, Shigella, and H influenzae. Ampicillin exerts its action by inhibiting the synthesis of bacterial cell wall. Absorption: Relatively well absorbed from the GI tract with peak plasma concentrations after 1-2 hr (oral); may be altered in the presence of food. Distribution: Widely distributed into the ascitic, pleural and joint fluids (therapeutic concentrations), CSF (small amounts except when the meninges are inflamed), bile (high concentrations); crosses the placenta and enters the breast milk (small amounts). Protein-binding: 20%. Metabolism: Converted to some extent to penicilloic acid; undergoes enterohepatic recycling. Excretion: Via the urine by glomerular filtration and tubular secretion; via the faeces. May be removed by haemodialysis. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Administration |
Should be taken on an empty stomach. (Take on an empty stomach 1 hr before or 2 hr after meals.) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Storage Conditions |
Injection: Store at 20-25°C. For admin: Use freshly prepared solutions. IV and IM solutions should be used within 1 hr after preparation. Intravenous: Store at 20-25°C. For admin: Use freshly prepared solutions. Intravenous (IV) and intramuscular (IM) solutions should be used within 1 hour after preparation. Oral: Store at 20-25°C. Parenteral: Store at 20-25°C. For admin: Use freshly prepared solutions. IV and IM solutions should be used within 1 hr after preparation. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ATC Classification |
J01CA01 - ampicillin ; Belongs to the class of penicillins with extended spectrum. Used in the systemic treatment of infections. S01AA19 - ampicillin ; Belongs to the class of antibiotics. Used in the treatment of eye infections. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Storage |
Injection: Store at 20-25°C. For admin: Use freshly prepared solutions. IV and IM solutions should be used within 1 hr after preparation. Intravenous: Store at 20-25°C. For admin: Use freshly prepared solutions. Intravenous (IV) and intramuscular (IM) solutions should be used within 1 hour after preparation. Oral: Store at 20-25°C. Parenteral: Store at 20-25°C. For admin: Use freshly prepared solutions. IV and IM solutions should be used within 1 hr after preparation. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Available As |
|
Ampicillin
Post Review about Ampicillin Click here to cancel reply.
Ampicillin Containing Brands
Ampicillin is used in following diseases
Drug - Drug Interactions of Ampicillin
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.